The global epilepsy drugs market valued for $6.94 Billion in 2022 and is estimated to reach $9.80 Billion by 2032, exhibiting a CAGR of 3.5% from 2023 to 2032.
Epilepsy is a neurological disorder that affects the brain and causes recurrent seizures. Seizures are sudden, abnormal electrical discharges in the brain that can cause a wide range of symptoms depending on the area of the brain affected. Symptoms of epilepsy include sudden and uncontrolled movements or convulsions, loss of consciousness, altered sensations, confusion, memory loss, and emotional changes. The frequency, duration, and severity of seizures vary among individuals with epilepsy. Epilepsy has multiple causes, including genetic factors, brain injuries, infections, brain tumors, stroke, developmental disorders, and other underlying neurological conditions.
The primary goal of treatment for epilepsy is to control or reduce the frequency and severity of seizures and minimize the side effects of medications. The antiepileptic drugs (AEDs) work by suppressing abnormal electrical activity in the brain. Epilepsy drugs, also known as antiepileptic drugs (AEDs) or antiseizure medications, are a class of medications used to manage and treat epilepsy. Epilepsy drugs work by reducing or preventing the occurrence of seizures, which are abnormal electrical activities in the brain.
The epilepsy drugs market growth is driven by factors such as the increase in prevalence of epilepsy, rise in awareness about epilepsy condition, and surge in geriatric population as they have higher risk of developing epilepsy. For instance, according to the World Health Organization (WHO), in February 2023, around 50 million people worldwide had epilepsy, making it one of the most common neurological diseases globally. In addition, from the same source, in high-income countries, there is an estimated 49 per 100,000 patients diagnosed with epilepsy each year. Thus, increase in prevalence of epilepsy condition and high burden of epilepsy are expected to foster the demand for medications to manage the seizures and drive the market growth.
Moreover, rise in demand for generic antiepileptic drugs has influenced the market growth. For instance, generic version of antiepileptics drugs such as levetiracetam are less expensive, more affordable, and accessible to wider population, thereby driving the market growth. Furthermore, rise in awareness about early diagnosis and treatment for epilepsy, which help to control seizures, further increases the demand for epilepsy drugs and drive growth of the market.
However, epilepsy drugs have potential adverse effects and safety concerns that hinder the market growth. Safety concerns related to side effects, drug interactions, and long-term safety profiles may impact the utilization of epilepsy drugs, especially if they are associated with serious risks. Safety concerns result in regulatory warnings or restrictions, decreased patient adherence, and reduced physician confidence in prescribing certain epilepsy drugs, which negatively affect the market growth. On the contrary, high growth potential in emerging countries owing to rise in awareness about early diagnosis and treatment offers lucrative opportunities to key players of the epilepsy drugs market.
The epilepsy drugs market is segmented on the basis of seizure type, drug generation, distribution channel, and region. By seizure type, the market is segregated into focal seizures, generalized seizures, and non-epileptic seizures. By drug generation, the market is categorized into first generation drugs, second generation drugs, and third generation drugs. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the epilepsy drugs market are Novartis AG, GlaxoSmithKline plc, Sanofi, UCB S.A., Abbott Laboratories, Bausch Health Companies, Inc, Viatris Inc., Johnson & Johnson, Sumitomo Pharma Co., Ltd, and H. Lundbeck A/S. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio. For instance, in November 2020, UCB S.A., a global pharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved VIMPAT (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients who are four years of age and older.
increase in demand for epilepsy drugs and rise in awareness about importance of early diagnosis and treatment is expected to offer profitable opportunities for the expansion of the market. However, side effects of epilepsy drugs such as drowsiness, fatigue, and gastrointestinal symptoms hinder the market growth.
The surge in incidences of epilepsy drives the demand for antiepileptic drugs and supports the market growth. Moreover, rise in awareness about increase in number of generic drug manufactures and increase in ageing population, as they are more prone to develop epilepsy, are some factors that further boost market growth.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to the rise in prevalence of epilepsy along with surge in geriatric population and presence of major key players in the region. However, Asia-Pacific is anticipated to witness notable growth owing to rise in healthcare awareness and increase in incidences of epilepsy.
Epilepsy is a neurological disorder that affects the brain and causes recurrent seizures. Seizures are sudden, abnormal electrical discharges in the brain that can cause a wide range of symptoms depending on the area of the brain affected. Symptoms of epilepsy include sudden and uncontrolled movements or convulsions, loss of consciousness, altered sensations, confusion, memory loss, and emotional changes. The frequency, duration, and severity of seizures vary among individuals with epilepsy. Epilepsy has multiple causes, including genetic factors, brain injuries, infections, brain tumors, stroke, developmental disorders, and other underlying neurological conditions.
The primary goal of treatment for epilepsy is to control or reduce the frequency and severity of seizures and minimize the side effects of medications. The antiepileptic drugs (AEDs) work by suppressing abnormal electrical activity in the brain. Epilepsy drugs, also known as antiepileptic drugs (AEDs) or antiseizure medications, are a class of medications used to manage and treat epilepsy. Epilepsy drugs work by reducing or preventing the occurrence of seizures, which are abnormal electrical activities in the brain.
The epilepsy drugs market growth is driven by factors such as the increase in prevalence of epilepsy, rise in awareness about epilepsy condition, and surge in geriatric population as they have higher risk of developing epilepsy. For instance, according to the World Health Organization (WHO), in February 2023, around 50 million people worldwide had epilepsy, making it one of the most common neurological diseases globally. In addition, from the same source, in high-income countries, there is an estimated 49 per 100,000 patients diagnosed with epilepsy each year. Thus, increase in prevalence of epilepsy condition and high burden of epilepsy are expected to foster the demand for medications to manage the seizures and drive the market growth.
Moreover, rise in demand for generic antiepileptic drugs has influenced the market growth. For instance, generic version of antiepileptics drugs such as levetiracetam are less expensive, more affordable, and accessible to wider population, thereby driving the market growth. Furthermore, rise in awareness about early diagnosis and treatment for epilepsy, which help to control seizures, further increases the demand for epilepsy drugs and drive growth of the market.
However, epilepsy drugs have potential adverse effects and safety concerns that hinder the market growth. Safety concerns related to side effects, drug interactions, and long-term safety profiles may impact the utilization of epilepsy drugs, especially if they are associated with serious risks. Safety concerns result in regulatory warnings or restrictions, decreased patient adherence, and reduced physician confidence in prescribing certain epilepsy drugs, which negatively affect the market growth. On the contrary, high growth potential in emerging countries owing to rise in awareness about early diagnosis and treatment offers lucrative opportunities to key players of the epilepsy drugs market.
The epilepsy drugs market is segmented on the basis of seizure type, drug generation, distribution channel, and region. By seizure type, the market is segregated into focal seizures, generalized seizures, and non-epileptic seizures. By drug generation, the market is categorized into first generation drugs, second generation drugs, and third generation drugs. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the epilepsy drugs market are Novartis AG, GlaxoSmithKline plc, Sanofi, UCB S.A., Abbott Laboratories, Bausch Health Companies, Inc, Viatris Inc., Johnson & Johnson, Sumitomo Pharma Co., Ltd, and H. Lundbeck A/S. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio. For instance, in November 2020, UCB S.A., a global pharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved VIMPAT (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients who are four years of age and older.
increase in demand for epilepsy drugs and rise in awareness about importance of early diagnosis and treatment is expected to offer profitable opportunities for the expansion of the market. However, side effects of epilepsy drugs such as drowsiness, fatigue, and gastrointestinal symptoms hinder the market growth.
The surge in incidences of epilepsy drives the demand for antiepileptic drugs and supports the market growth. Moreover, rise in awareness about increase in number of generic drug manufactures and increase in ageing population, as they are more prone to develop epilepsy, are some factors that further boost market growth.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to the rise in prevalence of epilepsy along with surge in geriatric population and presence of major key players in the region. However, Asia-Pacific is anticipated to witness notable growth owing to rise in healthcare awareness and increase in incidences of epilepsy.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epilepsy drugs market analysis from 2022 to 2032 to identify the prevailing epilepsy drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the epilepsy drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global epilepsy drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Seizure Type
- Focal seizures
- Generalized seizures
- Non-epileptic seizures
By Drugs Generation
- First Generation Drugs
- Second Generation Drugs
- Third Generation Drugs
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- Bausch Health Companies, Inc.
- GlaxoSmithKline plc
- H. Lundbeck A/S
- Johnson & Johnson
- Novartis AG
- Sanofi
- Sumitomo Pharma Co., Ltd
- UCB S.A.
- Viatris Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: EPILEPSY DRUGS MARKET, BY SEIZURE TYPE
CHAPTER 5: EPILEPSY DRUGS MARKET, BY DRUGS GENERATION
CHAPTER 6: EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: EPILEPSY DRUGS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Bausch Health Companies, Inc.
- GlaxoSmithKline plc
- H. Lundbeck A/S
- Johnson & Johnson
- Novartis AG
- Sanofi
- Sumitomo Pharma Co., Ltd
- UCB S.A.
- Viatris Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
